Botulinum toxin is best known cosmetically, but one of its most consequential uses is medical: controlling severe sweating that resists conventional therapy. For patients with hyperhidrosis, the benefit is functional – the difference between participating fully in daily life and constantly managing visible perspiration. This review draws on the FDA prescribing label, peer-reviewed trials, and the International Hyperhidrosis Society.
Defining the condition
Hyperhidrosis is sweating in excess of what thermoregulation requires, to a degree that disrupts daily function. It falls into two categories. Primary focal hyperhidrosis affects discrete areas – underarms, palms, soles, or face – with no underlying cause. Secondary hyperhidrosis results from another factor, such as medication, thyroid disease, menopause, or infection, and a clinical workup should exclude these before any focal treatment is considered.
This distinction is central to how Botox is approved. OnabotulinumtoxinA, marketed by AbbVie as Botox, received FDA approval in 2004 for severe primary axillary hyperhidrosis, the underarms, in patients 18 and older who have not responded to antiperspirants. Use elsewhere on the body, including the palms, is off-label: not improper or unstudied, but not formally cleared by the agency.
Mechanism of action
Sweat glands are activated by acetylcholine, a neurotransmitter released by the nerve endings that supply them. Botox interrupts this signal. Injected intradermally, it blocks acetylcholine release at the nerve terminals, so the glands in the treated area do not activate. Two consequences follow: the effect is strictly local, limited to the injected region, and it is temporary, because nerve terminals gradually regain function. This is why treatment must be repeated.
Efficacy
The supporting evidence is strong and derived from randomized trials. In a placebo-controlled European study of 320 patients (Naumann et al., BMJ, 2001), Botox produced at least a 50% reduction in measured underarm sweat at four weeks in the large majority of patients, versus a placebo response in the mid-30s percent.
A prospective study (Archives of Dermatology, 2003) followed patients over 16 months and reported four-week response rates of 96%, 91%, and 83% after the first, second, and third treatments. A 52-week, double-blind, placebo-controlled pivotal trial supporting approval found the effect began within about a week and lasted six months or longer, with significant quality-of-life improvement.
Efficacy extends to adolescents, though the label begins at 18. An open-label study of 141 patients aged 12 to 17 found that roughly 79% to 93% achieved a 75%-or-greater reduction in sweat production at week four, with a median duration near 4.5 months.
The procedure
The treatment area is typically mapped using the starch-iodine (Minor’s) test, which stains actively sweating skin dark. Injections are shallow and numerous, placed in a grid across each underarm. The FDA-labeled dose is 100 units total — 50 per axilla. Relief generally appears within a week and lasts several months; real-world re-treatment occurs roughly every six to seven months, with considerable individual variation. Botox is not interchangeable with other botulinum toxin products; the FDA label states its potency units cannot be converted into those of Dysport or Xeomin.
Safety
For axillary treatment, the procedure is well tolerated. The most common effects are injection-site pain, bruising, and occasional headache or transient muscle soreness. Roughly 4.5% of patients report increased sweating elsewhere on the body, usually resolving within a month, and transient upper-limb weakness has been reported in under 1% of cases.
Palmar treatment carries additional considerations: temporary weakness in the small muscles controlling fine grip, and significant injection pain often requiring nerve blocks — factors that reinforce its off-label, more cautious status. As with all botulinum toxin products, the label carries a boxed warning regarding potential spread of toxin effect, though no definitive serious cases have been reported at the 100-unit hyperhidrosis dose. Serious hypersensitivity reactions, including anaphylaxis, are rare. These risks underscore the importance of an experienced injector and full disclosure of medical history.
Conclusion
For severe underarm hyperhidrosis unresponsive to antiperspirants, Botox is among the best-supported treatments in dermatology: rapid in onset, effective in most patients, and associated with mild, short-lived adverse effects. The principal limitations are its temporary nature, requiring repeat treatment two to three times yearly, and that its strongest evidence and sole FDA approval apply to the underarms. Patients considering it should begin with a diagnostic evaluation to confirm the condition is primary and assess individual suitability.
This article is for general information and is not medical advice. Treatment decisions should be made with a qualified clinician.
